S11 E5: Keep Marching On: Changing the Story of Pancreatic Cancer
Published Date:
With podcast host, Ginger Blackmon, and featuring Julie Fleshman, JD, MBA, President and CEO of the Pancreatic Cancer Action Network (PanCAN).
Julie shares how losing her father to pancreatic cancer led her to PanCAN, where she became the organization’s first employee and has spent more than 25 years helping drive change for the pancreatic cancer community.
Julie and Ginger discuss PanCAN’s comprehensive approach to supporting patients and families through patient services, education, clinical trial and specialist resources, research funding, and advocacy. Julie also explains how individual patient and caregiver stories can become a powerful collective voice for advancing pancreatic cancer research and influencing federal investment.
The conversation also looks at the growing momentum in pancreatic cancer, including advances in KRAS-targeted therapies, opportunities in early detection and combination treatments, and the potential role of AI. Julie shares why connecting patients and healthcare professionals with PanCAN resources can make an important difference as families navigate an overwhelming diagnosis.
Learn more about PanCAN and its resources at PanCAN.org
More Episodes
S11 E4: From Data to Decisions: Decoding Prostate Cancer Updates
What do the latest prostate cancer advances actually mean in practice? Manojkumar Bupathi, MD, and Matthew Garmezy, MD, unpack the evolving evidence and how oncology teams can apply it to real-world treatment decisions.
September 9, 2026
S11 E3: Beyond Borders: Bringing Cancer Treatment Within Reach
Pat Garcia-Gonzalez, Co-Founder and CEO of The Max Foundation, shares her deeply personal journey from losing her stepson to leukemia to building a global movement for equitable access to cancer treatment and care.
September 2, 2026
S11 E2: Navigating Life After Cancer
Geoffrey Rogow shares a candid look at cancer survivorship and the medical, emotional, and practical challenges that continue long after treatment ends.
August 24, 2026